Prevalence of Wegener’s Granulomatosis in 9 Major Markets 2015-2025

42 pages


This report provides the current prevalence of Wegener’s Granulomatosis in 9 major markets.


Wegener’s Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalence for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

  • Renal complications
  • Other autoimmune conditions
  • Respiratory complications
  • Neurological complications
  • Various vascular manifestations
  • Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global WG’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of WG and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on WG’s prevalence.
  • Identify sub-populations within WG which require treatment.
  • Gain an understanding of the specific markets that have the largest number of WG patients.

You may also like…

    Epiomic Database


    A robust source of evidence-based patients for diseases, hospital admissions and procedures across healthcare markets.

Download your FREE table of contents!

Buy Report

This report provides the current prevalence of Wegener’s Granulomatosis in 9 major markets.